Episteme Prognostics has filed a notice of an exempt offering of securities to raise $6,017,000.00 in New Funding.

According to filings with the U.S. Securities and Exchange Commission, Episteme Prognostics is raising up to $6,017,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Episteme Prognostics
Episteme Prognostics is a precision medicine company pioneering epigenetic diagnostics to transform how cancer therapy is selected and delivered. Our mission is to help oncologists identify which patients will truly benefit from specific chemotherapies, starting with pancreatic cancer. Our lead test, PancEpistemeDx, is a DNA based, laboratory developed test that uses a proprietary ATAC array platform to assess chromatin accessibility and predict chemotherapy response in pancreatic ductal adenocarcinoma (PDAC). In clinical studies, the technology has demonstrated high accuracy in distinguishing responders and non responders to frontline chemotherapy, addressing a major unmet need in a cancer where only a minority of patients benefit from standard regimens. Founded by academic leaders in surgical oncology and epigenetics, Episteme Prognostics is supported by NIH funding, private investment, and active regulatory engagement as we advance our platform toward clinical adoption. .

To learn more, visit https://www.epistemedx.com/
LinkedIn: https://www.linkedin.com/company/episteme-prognostics/

Contact:
Surajit Dhara, Chief Executive Officer
https://www.linkedin.com/in/surajit-dhara-2469aa7/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.